Treatment results in patients with myeloma-related renal impairment
Authors:
R. Šafránek 1,2; J. Radocha 3; V. Maisnar 3; A. Malá 1; S. Dusilová Sulková 1,2
Authors‘ workplace:
Hemodialyzační středisko, Fakultní nemocnice Hradec Králové
1; Katedra interních oborů, Lékařská fakulta v Hradci Králové, Univerzita Karlova
2; IV. interní hematologická klinika, Fakultní nemocnice a Lékařská fakulta Univerzity Karlovy v Hradci Králové
3
Published in:
Klin. Biochem. Metab., 24, 2016, No. 3, p. 133-135
Overview
Objective:
Analysis of treatment results of myeloma-related renal impairment with regard to hemodialysis treatment and mortality.
Design:
Retrospective analysis of single center data.
Methods:
Analysis of data in registry of monoclonal gammapathies. Patients with newly diagnosed multiple myeloma between June 2007 and June 2015 were included in the study.
Results:
Myeloma was newly diagnosed in 443 patients. Renal impairment at the time of diagnosis was found in 101 (22.8 %) patients. Hemodialysis treatment was started in 58 (13 %) patients. A third of patients treated with bortezomib based regimen recovered renal function. However, no patient recovered renal function in a group that was treated with regimen without bortezomib.
Conclusion:
Bortezomib inclusion into treatment regimen in patients with myeloma-related renal failure led to recovery of renal function in a third of patients. Mortality of patients with myeloma-related renal failure is still very high compared to patients with renal failure due to other causes.
Keywords:
multiple myeloma, hemodialysis, bortezomib.
Sources
1. Dimopoulos, M. A., Kastritis, E., Rosinol, L. et al. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia, 2008, 22, p. 1485-1493.
2. Bladé, J., Fernández-Llama, P., Bosch, F. et al. Renal failure in multiple myeloma: presenting features and predictors of outcome in 94 patients from a single institution. Arch. Intern. Med., 1998, 158 (17): p. 1889-1893.
3. The International Myeloma Working Group. Criteria for the classification of monoclonal gammapathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br. J. Haematol., 2003, 121: p. 749-757.
4. Durie, B. G. A clinical staging system for multiple mye-loma. Cancer 1975, 36, p. 842-854.
5. Diagnostika a léčba mnohočetného myelomu 2012. Transfuze Hematol. dnes. 2012, Suppl. 1: s. 1-89.
6. Dimopoulos, M. A. et al. International myeloma working group recommendations for the diagnosis and mana-gement of myeloma-related renal impairment. J. Clin. Oncol. 2016, 34 (13), p. 1544-1557.
7. Statistická ročenka dialyzační léčby v České republice, Česká nefrologická společnost. Dostupný na http://www.nefrol.cz/odbornici/dialyzacni-statistika.
Labels
Clinical biochemistry Nuclear medicine Nutritive therapistArticle was published in
Clinical Biochemistry and Metabolism
2016 Issue 3
Most read in this issue
- Detection of oligoclonal IgM in cerebrospinal fluid
- Vitamins in critically ill patients.
- Advances in immunoassays by luminescence and electrochemical detection
- New diagnostic criteria of multiple myeloma